GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 25, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS

Goodwill

The following table provides a rollforward of the Company’s goodwill:

			Adjustments to Goodwill						Adjustments to Goodwill
	December 28, 2019		Acquisitions		Foreign Exchange		December 26, 2020		Acquisitions		Divestitures		Foreign Exchange		December 25, 2021
	(in thousands)
RMS	$	56,586	$	229,654	$	1,519	$	287,759	$	—	$	(4,129)	$	(106)	$	283,524
DSA	2,350,223		(629)		33,536		2,383,130		123,091		—		(28,715)		2,477,506
Manufacturing	138,756		—		4,523		143,279		851,828		(27,764)		(11,492)		955,851
Gross carrying amount	2,545,565		229,025		39,578		2,814,168		974,919		(31,893)		(40,313)		3,716,881
Accumulated impairment loss - DSA	(1,005,000)		—		—		(1,005,000)		—		—		—		(1,005,000)
Goodwill	$	1,540,565					$	1,809,168							$	2,711,881

Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2021, 2020 and 2019, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired.

The increase in goodwill during fiscal year 2021 related primarily to the acquisitions of Cognate and Vigene in the Manufacturing reportable segment and Distributed Bio and Retrogenix in the DSA reportable segment. The decreases in the RMS and Manufacturing reportable segments was a result of the sales of RMS Japan and CDMO Sweden, respectively. The increase in goodwill during fiscal year 2020 related primarily to the acquisitions of HemaCare and Cellero in the RMS reportable segment.

Intangible Assets, Net

The following table displays intangible assets, net by major class:

	December 25, 2021						December 26, 2020
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
	(in thousands)
Backlog	$	12,577	$	(9,517)	$	3,060	$	29,233	$	(29,233)	$	—
Technology	135,764		(95,454)		40,310		130,907		(81,305)		49,602
Trademarks and trade names	13,086		(3,448)		9,638		15,870		(5,648)		10,222
Other	35,231		(8,445)		26,786		20,903		(14,633)		6,270
Other intangible assets	196,658		(116,864)		79,794		196,913		(130,819)		66,094
Client relationships	1,475,757		(494,359)		981,398		1,137,331		(415,826)		721,505
Intangible assets	$	1,672,415	$	(611,223)	$	1,061,192	$	1,334,244	$	(546,645)	$	787,599

The increase in intangible assets, net during fiscal year 2021 related primarily to the acquisitions of Cognate, Distributed Bio, Retrogenix, and Vigene.

Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2021, 2020 and 2019 was $124.9 million, $111.9 million and $89.5 million, respectively. As of December 25, 2021, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:

Fiscal Year	Amortization Expense
	(in thousands)
2022	$	143,202
2023	131,385
2024	118,295
2025	110,830
2026	103,485